Accuray(ARAY)
Focus: Accuray is a publicly traded oncology-focused medical device and therapy company specializing in directed radiation therapy platforms including CyberKnife stereotactic radiosurgery and intensity-modulated radiation therapy. The company operates at mid-cap scale with ~$450M in annual revenue.
Profile data last refreshed 53m ago · AI intelligence enriched 1mo ago
Funding Stage
PUBLIC
Open Jobs
38+14 this month
Growing — net +14 jobs in 30d
31 jobs added vs 17 removed. Steady team buildout.
Should You Work at Accuray?
AI assessmentSuitable for oncology engineers and device developers seeking stable work on established radiation therapy platforms, but limited growth trajectory and tight cash position reduce career acceleration potential.
Why Work Here
- Strong oncology pipeline with 11 active programs spanning prostate, endometrial, hepatocellular, lung, and anal cancers, providing diverse clinical exposure.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$459M
Pipeline & Clinical Trials
CyberKnife Stereotactic Radiotherapy
Non-small Cell Lung CancerClinical Trials (1)
NCT00840749Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
N/AHelp build intelligence for Accuray
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.